Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Hyogo University

InstitutionResearch output, impact & collaborations

Hyogo University is a research organisation in Kakogawa, JP. OpenAlex records 4,247 works and 68,499 citations for it. 1,817 researchers list it as their most recent affiliation.

4,247
Works
68,499
Citations
1,817
Researchers
50.7
Avg h-index

How has Hyogo University's publication output changed over time?

ScholarIQpublication output · 2016–2022

Output declined50% over the shown period — from 2 works in 2016 to 1 in 2022.

2
3
2
3
1
1
201620172018201920212022

Who are the most-cited researchers behind Hyogo University?

ScholarIQtop researchers by citations
1
Daichi Fujimoto · Lung Cancer Treatments and Mutations
243 works4,081 citations

What are the most-cited papers on Hyogo University?

ScholarIQmost cited works
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka, Daichi Fujimoto, Takeshi Morimoto, Hayato Kawachi, Munehiro Ito, Yuki Sato, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Keiichiro Uehara, Yukihiro Imai, Kaori Shintani‐Ishida, Junya Fukuoka, Keisuke Tomii
Journal of Thoracic Oncology. 2017379 CitationsOPEN ACCESS
Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis
Hiroki Nishikawa, Hirayuki Enomoto, Akio Ishii, Yoshinori Iwata, Yuho Miyamoto, Noriko Ishii, Yukihisa Yuri, Kunihiro Hasegawa, Chikage Nakano, Takashi Nishimura, Kazunori Yoh, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Tomoyuki Takashima, Ryo Takata, Hiroko Iijima, Shuhei Nishiguchi
S173726759. 2017195 CitationsOPEN ACCESS
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto
JAMA Oncology. 2021187 CitationsOPEN ACCESS
“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic, Hyun J. Lim, Julien Adam, Penny J. Barnes, Gilbert Bigras, Anthony W.H. Chan, Carol C. Cheung, Jin-Haeng Chung, Christian Couture, Pierre Fiset, Daichi Fujimoto, Gang Han, Fred R. Hirsch, Marius Ilié, Diana N. Ionescu, Chao Li, Enrico Munari, Katsuhiro Okuda, M. Ratcliffe, David L. Rimm, Catherine Ross, Rasmus Røge, Andreas H. Scheel, Ross A. Soo, Paul E. Swanson, Maria Tretiakova, Ka‐Fai To, Gilad W. Vainer, Hangjun Wang, Zhaolin Xu, Dirk Zielinski, Ming‐Sound Tsao
S33606366. 2019178 CitationsOPEN ACCESS
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, Reiko Kaji, Hiroshige Yoshioka, Takashi Seto, Miyako Satouchi, Yasuo Iwamoto, Masashi Kanehara, Daichi Fujimoto, Norihiko Ikeda, Haruyasu Murakami, Haruko Daga, Tetsuya Oguri, Isao Goto, Fumio Imamura, Shunichi Sugawara, Hideo Saka, Naoyuki Nogami, Shunichi Negoro, Kazuhiko Nakagawa, Yoichi Nakanishi
Journal of Clinical Oncology. 2016160 Citations

How much of the research on Hyogo University is open access?

ScholarIQopen access share
58%OPEN ACCESS
Gold
25%
Green
0%
Hybrid
25%
Bronze
8%
Closed
42%

Related on ScholarIQ

Acute Ischemic Stroke Management
Top Topic
Hepatocellular Carcinoma Treatment and Prognosis
Top Topic
Cerebrovascular and Carotid Artery Diseases
Top Topic
Inflammatory Bowel Disease
Top Topic
Cancer Immunotherapy and Biomarkers
Top Topic
Colorectal Cancer Treatments and Studies
Top Topic
470M+ articles · free account